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Table 1
ED Group
(n¼46)
Non-ED Group
(n¼46) P value
Age (years) 54.68.5 53.98.0 0.6
Gender (female, %) 71.7 73.9 0.5
Duration of
Type 2 DM (mean month)
50.3 42.6 0.1
History of (%)
Hypertension 80.4 78.3 0.5
Smoke 28.3 19.6 0.2
Fasting glucose (mg/dL) 20280 18970 0.3
Creatinin (mg/dL) 0.860.19 0.880.19 0.4
Triglyceride (mg/dL) 208115 18283 0.2
Total Cholesterol (mg/dL) 20551 19945 0.5
LDL-C (mg/dL) 12437 11739 0.3
HDL-C (mg/dL) 419 4310 0.5
HgA1C (%) 8.71.9 7.91.6 0.038
CRP (mg/L) 5.5 5.0 4.5 5.1 0.3
Waist length (cm) 11112 1088 0.1
BMI(kg/m2) 32.45.8 31.13.7 0.1
Adropin (ng/mL) 3.040.79 4.671.43 <0.001
The clinical and biochemical characteristics of type 2 diabetes mellitus patients
Table 2
beta t p
Adropin -,568 -6,730 <0,001
HgA1C ,180 2,129 0,036
The linear regression analysis for endothelial dysfunction in type 2 DM
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Objective: This study investigated the role of plasma adropin levels to show endo-
thelial dysfunction in individuals with type 2 diabetes mellitus, and to compare these
with ﬂow mediated dilatation.
Methods: A total of 92 individuals with diagnosed type 2 diabetes mellitus were
included and divided into two groups, according to their brachial ﬂow-mediatedC82 JACC Vdilatation. The endothelial dysfunction group consisted of 46 participants with ﬂow
mediated dilatation change <7%, while 46 participants with ﬂow-mediated dilatation
change >7% were accepted as the non-endothelial dysfunction group. Venous blood
samples were taken from all study participants, and plasma adropin levels were
measured using an enzyme-linked immunosorbent assay kit.
Results: The baseline characteristics of the patients were summarized in Table 1. The
mean ﬂow mediated dilatation values were 13.24.9% in Non- Endothelial
Dysfunction Group and 3.53.4% in Endothelial Dysfunction Group. Figure 1
shows the difference of plasma adropin levels of patients between two group. The
mean plasma adropin levels were found 3.040.79 ng/mL in ED Group and
4.671.43 ng/mL in Non-ED group, p<0.001. The mean HgA1C levels were
signiﬁcantly higher in Endothelial Dysfunction Group than Non- Endothelial
Dysfunction Group (respectively, 8.71.9% vs 7.91.6%, p<0.038). Plasma
adropin levels have positive weak correlation with body mass index (r¼0.171,
p¼0.045) and they were signiﬁcantly positive correlated with ﬂow mediated
dilatation values (r¼0.537, p<0.001). In the linear regression analysis, adropin and
HgA1C were found to be independent risk factors for endothelial dysfunction in
type 2 diabetes mellitus patients (Table 2).
Conclusion: Adropin is a new marker for use in demonstrating endothelial
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